Solid forms of nilotinib hydrochloride
US9376419B2 · kind B2 · utility
6Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2013 |
| Grant date | Jun 28, 2016 |
| Priority date | — |
| Expiry date | Oct 15, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.